In patients with PNH from the TRIUMPH study, significant reductions in the level of NT-proBNP (p < 0.001), in addition to clinically meaningful improvements in dyspnea, were observed in eculizumab-treated patients compared with individuals receiving placebo.34 The gene discussed is NPPB; the disease is paroxysmal nocturnal hemoglobinuria.